Latest TroVax Stories
ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Retrospective Study of Roswell Park Patients Documents Safety and Benefit of Complex Immunotherapy Buffalo, NY (PRWEB) May 06, 2014 A retrospective study
LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash.
ThermoDox Demonstrates Impressive Response Rate in Refractory Patients LAWRENCEVILLE, N.J., Feb.
WORCESTER, Mass. and TORONTO, Feb.
AUSTIN, Texas, Jan.
Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE,
- An armed gangster.